Trials / Active Not Recruiting
Active Not RecruitingNCT04854005
Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation
Selective Use of ALND in N1 HR+/HER2- Breast Cancer Patients With 1 or 2 Positive Sentinel Lymph Nodes Undergoing Upfront Breast Surgery and Adjuvant Radiation: A Prospective Study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 78 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out how often the researchers can avoid an ALND in patients with early-stage, node-positive HR+/HER2- breast cancer who are having upfront surgery. The study researchers think that, if AUS before surgery can help identify people who may have up to 3 affected lymph nodes, it will be possible to perform the less radical standard SLNB during surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Breast surgery | Patients will undergo SLNB with single or dual-tracer lymphatic with technetium-99m sulfur colloid either lymphazurin or methylene blue dye, per institution standard, in accordance with routine clinical practice. |
Timeline
- Start date
- 2021-04-20
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2021-04-22
- Last updated
- 2026-01-12
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04854005. Inclusion in this directory is not an endorsement.